The First International Symposium on Pheochromocytoma ... Inadequate methods to distinguish malignant from benign tumors and a lack of effective treatments for malignancy are important problems ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J. Clin.

AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Signs and symptoms of adrenal insufficiency include: Sometimes adrenal nodules show up on an imaging scan (CT scan or MRI ... possible excess hormone production or suspicion of cancer. A ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Pathologic examination should distinguish primary or metastatic pheochromocytomas and paragangliomas from other endocrine or nonendocrine tumors and flag tumors with features suggestive of ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.